References
- Alvarez MM, Liu JC, Trujillo-de Santiago G, et al. (2016). Delivery strategies to control inflammatory response: modulating M1-M2 polarization in tissue engineering applications. J Control Release 240:349–63.
- Andersson U, Tracey KJ. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139–62.
- Bhatia M, Moochhala S. (2004). Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 202:145–56.
- Buehler PW, D’Agnillo F, Schaer DJ. (2010). Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. Trends Mol Med 16:447–57.
- Coburn RF. (1970). The carbon monoxide body stores. Ann NY Acad Sci 174:11–22.
- Erridge C. (2010). Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87:989–99.
- Flegel WA, Natanson C, Klein HG. (2014). Does prolonged storage of red blood cells cause harm? Br J Haematol 165:3–16.
- Gukovskaya AS, Gukovsky I, Algül H, Habtezion A. (2017). Autophagy, Inflammation, and Immune Dysfunction in the Pathogenesis of Pancreatitis. Gastroenterology 153:1212–26.
- Leser HG, Gross V, Scheibenbogen C, et al. (1991). Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 101:782–5.
- Leung PS, Chan YC. (2009). Role of oxidative stress in pancreatic inflammation. Antioxid Redox Signal 11:135–65.
- Liu Y, Zhou D, Long FW, et al. (2016). Resolvin D1 protects against inflammation in experimental acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 310:G303–9.
- Luan ZG, Zhang XJ, Yin XH, et al. (2013). Downregulation of HMGB1 protects against the development of acute lung injury after severe acute pancreatitis. Immunobiology 218:1261–70.
- Montecucco F, Mach F, Lenglet S, et al. (2014). Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. Eur J Clin Invest 44:940–50.
- Motterlini R, Otterbein LE. (2010). The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 9:728–43.
- Nagao S, Taguchi K, Miyazaki Y, et al. (2016a). Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis. J Control Release 234:49–58.
- Nagao S, Taguchi K, Sakai H, et al. (2014). Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. Biomaterials 35:6553–62.
- Nagao S, Taguchi K, Sakai H, et al. (2016b). Carbon monoxide-bound hemoglobin vesicles ameliorate multiorgan injuries induced by severe acute pancreatitis in mice by their anti-inflammatory and antioxidant properties. Int J Nanomedicine 11:5611–20.
- Ogaki S, Taguchi K, Maeda H, et al. (2015). Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock. Biochem Pharmacol 97:310–19.
- Otterbein LE, Bach FH, Alam J, et al. (2000). Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6:422–8.
- Parodi A, Molinaro R, Sushnitha M, et al. (2017). Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials 147:155–68.
- Rochette L, Cottin Y, Zeller M, Vergely C. (2013). Carbon monoxide: mechanisms of action and potential clinical implications. Pharmacol Ther 137:133–52.
- Roderique JD, Josef CS, Feldman MJ, Spiess BD. (2015). A modern literature review of carbon monoxide poisoning theories, therapies, and potential targets for therapy advancement. Toxicology 334:45–58.
- Sakai H. (2017). Overview of potential clinical applications of hemoglobin vesicles (HbV) as artificial red cells, evidenced by preclinical studies of the Academic Research Consortium. Jfb 8:10.
- Sakai H, Horinouchi H, Tsuchida E, Kobayashi K. (2009). Hemoglobin vesicles and red blood cells as carriers of carbon monoxide prior to oxygen for resuscitation after hemorrhagic shock in a rat model. Shock 31:507–14.
- Sakai H, Sato A, Masuda K, et al. (2008a). Encapsulation of concentrated hemoglobin solution in phospholipid vesicles retards the reaction with NO, but not CO, by intracellular diffusion barrier. J Biol Chem 283:1508–17.
- Sakai H, Sato A, Sobolewski P, et al. (2008b). NO and CO binding profiles of hemoglobin vesicles as artificial oxygen carriers. Biochim Biophys Acta 1784:1441–7.
- Savitsky JP, Doczi J, Black J, Arnold JD. (1978). A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 23:73–80.
- Sheikhpour M, Barani L, Kasaeian A. (2017). Biomimetics in drug delivery systems: a critical review. J Control Release 253:97–109.
- Shrivastava P, Bhatia M. (2010). Essential role of monocytes and macrophages in the progression of acute pancreatitis. World J Gastroenterol 16:3995–4002.
- Sica A, Mantovani A. (2012). Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–95.
- Su Z, Zhang P, Yu Y, et al. (2016). HMGB1 facilitated macrophage reprogramming towards a proinflammatory M1-like phenotype in experimental autoimmune myocarditis development. Sci Rep 6:21884.
- Taguchi K, Yamasaki K, Maruyama T, Otagiri M. (2017a). Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers. Jfb 8:11.
- Taguchi K, Yamasaki K, Sakai H, et al. (2017b). The use of hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders. J Pharm Sci 106:2392–400.
- Wang H, Bloom O, Zhang M, et al. (1999a). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–51.
- Wang H, Vishnubhakat JM, Bloom O, et al. (1999b). Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389–92.
- Wynn TA, Chawla A, Pollard JW. (2013). Macrophage biology in development, homeostasis and disease. Nature 496:445–55.
- Xue J, Habtezion A. (2014). Carbon monoxide-based therapy ameliorates acute pancreatitis via TLR4 inhibition. J Clin Invest 124:437–47.
- Yu E, Goto M, Ueta H, et al. (2016). Expression of area-specific M2-macrophage phenotype by recruited rat monocytes in duct-ligation pancreatitis. Histochem Cell Biol 145:659–73.
- Zhou MT, Chen CS, Chen BC, et al. (2010). Acute lung injury and ARDS in acute pancreatitis: mechanisms and potential intervention. World J Gastroenterol 16:2094–9.